In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.Amgen stock is trading lower as the data seemed to be below expectations.Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent ...